The successful stability validation of XPro for 24 months is a critical milestone for INmune Bio, indicating the product's readiness for the next phase of clinical trials and eventual commercialization. The development of a novel immunogenicity assay further supports the regulatory and commercial advancement of XPro. These developments are likely to be viewed positively by investors, as they demonstrate progress in the product's lifecycle and increase the likelihood of successful commercialization, potentially leading to an increase in the company's stock price in the short term.